Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

University of Glasgow

www.gla.ac.uk

Latest From University of Glasgow

Life Science Start-Ups: Tech Transfer Deals, November 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Tech Transfers column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced September through October 2013.

BioPharmaceutical Medical Device

Deals Of The Week: Academic Drug-Discovery Group’s Work Catching Industry’s Notice

As academic labs fill gaps in discovery work once performed by biopharma companies, Roche is confident that a U.S. consortium of academic drug-discovery units will lead to broader partnerships between industry and academia and within the academy itself. Plus, MedImmune acquires ADC specialist Spirogen and other deals from the past week.

BioPharmaceutical United States

Recent Tech Transfer Deals, May 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Tech Transfers column provides a monthly update on licensing agreements between universities or other research institutions and biopharma, medtech, and diagnostic start-ups.

BioPharmaceutical Medical Device

Virttu Biologics Ltd.

Despite a long history of disappointments, many experts now agree that viral therapy of cancer could soon become a reality. Accumulating clinical evidence indicates that researchers have figured out how to modify and enhance viruses in ways that make them both safe and effective. For its part, Virttu Biologics Ltd. is developing a single-deletion variant of HSV it calls SEPREHVIR. Research carried out at Virttu, as well as at the University of Glasgow where the core technology was developed, shows that the mutated virus is taken up by and remains in tumor tissue, without infecting surrounding healthy tissue.

BioPharmaceutical
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register